vs
BioNexus Gene Lab Corp（BGLC）与BillionToOne, Inc.（BLLN）财务数据对比。点击上方公司名可切换其他公司
BillionToOne, Inc.的季度营收约是BioNexus Gene Lab Corp的172.7倍（$83.5M vs $483.8K）。BillionToOne, Inc.净利率更高（6.8% vs -214.2%，领先221.0%）。BillionToOne, Inc.同比增速更快（117.4% vs -80.8%）。BillionToOne, Inc.自由现金流更多（$6.5M vs $960.1K）
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
BGLC vs BLLN — 直观对比
营收规模更大
BLLN
是对方的172.7倍
$483.8K
营收增速更快
BLLN
高出198.2%
-80.8%
净利率更高
BLLN
高出221.0%
-214.2%
自由现金流更多
BLLN
多$5.5M
$960.1K
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $483.8K | $83.5M |
| 净利润 | $-1.0M | $5.7M |
| 毛利率 | -0.8% | 69.9% |
| 营业利润率 | -213.5% | 11.5% |
| 净利率 | -214.2% | 6.8% |
| 营收同比 | -80.8% | 117.4% |
| 净利润同比 | -197.5% | 138.3% |
| 每股收益（稀释后） | — | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGLCBLLN
| Q4 25 | $483.8K | — | ||
| Q3 25 | $2.5M | $83.5M | ||
| Q2 25 | $2.3M | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $2.6M | $38.4M | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $2.4M | — |
净利润BGLCBLLN
| Q4 25 | $-1.0M | — | ||
| Q3 25 | $-709.0K | $5.7M | ||
| Q2 25 | $-616.2K | — | ||
| Q1 25 | $-623.3K | — | ||
| Q4 24 | $-348.3K | — | ||
| Q3 24 | $-1.3M | $-14.9M | ||
| Q2 24 | $199.1K | — | ||
| Q1 24 | $-103.8K | — |
毛利率BGLCBLLN
| Q4 25 | -0.8% | — | ||
| Q3 25 | 14.8% | 69.9% | ||
| Q2 25 | 16.3% | — | ||
| Q1 25 | 16.1% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 12.4% | 52.6% | ||
| Q2 24 | 14.6% | — | ||
| Q1 24 | 15.3% | — |
营业利润率BGLCBLLN
| Q4 25 | -213.5% | — | ||
| Q3 25 | -27.6% | 11.5% | ||
| Q2 25 | -27.0% | — | ||
| Q1 25 | -28.9% | — | ||
| Q4 24 | -16.5% | — | ||
| Q3 24 | -50.9% | -32.9% | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | -3.3% | — |
净利率BGLCBLLN
| Q4 25 | -214.2% | — | ||
| Q3 25 | -27.9% | 6.8% | ||
| Q2 25 | -27.3% | — | ||
| Q1 25 | -29.2% | — | ||
| Q4 24 | -13.8% | — | ||
| Q3 24 | -51.1% | -38.8% | ||
| Q2 24 | 10.1% | — | ||
| Q1 24 | -4.4% | — |
每股收益（稀释后）BGLCBLLN
| Q4 25 | — | — | ||
| Q3 25 | $-0.40 | $0.10 | ||
| Q2 25 | $-0.34 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $0.55 | — | ||
| Q3 24 | $-0.75 | $-1.47 | ||
| Q2 24 | $0.11 | — | ||
| Q1 24 | $-0.01 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $195.2M |
| 总债务越低越好 | — | $55.0M |
| 股东权益账面价值 | $8.6M | $-239.5M |
| 总资产 | $9.3M | $327.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BGLCBLLN
| Q4 25 | $2.5M | — | ||
| Q3 25 | — | $195.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
总债务BGLCBLLN
| Q4 25 | — | — | ||
| Q3 25 | — | $55.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BGLCBLLN
| Q4 25 | $8.6M | — | ||
| Q3 25 | $6.8M | $-239.5M | ||
| Q2 25 | $7.5M | — | ||
| Q1 25 | $7.8M | — | ||
| Q4 24 | $8.3M | — | ||
| Q3 24 | $9.4M | $-242.9M | ||
| Q2 24 | $9.5M | — | ||
| Q1 24 | $9.3M | — |
总资产BGLCBLLN
| Q4 25 | $9.3M | — | ||
| Q3 25 | $7.6M | $327.5M | ||
| Q2 25 | $9.4M | — | ||
| Q1 25 | $9.5M | — | ||
| Q4 24 | $10.4M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $11.1M | — | ||
| Q1 24 | $11.2M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $961.1K | $13.8M |
| 自由现金流经营现金流 - 资本支出 | $960.1K | $6.5M |
| 自由现金流率自由现金流/营收 | 198.5% | 7.7% |
| 资本支出强度资本支出/营收 | 0.2% | 8.8% |
| 现金转化率经营现金流/净利润 | — | 2.42× |
| 过去12个月自由现金流最近4个季度 | $-1.9M | — |
8季度趋势，按日历期对齐
经营现金流BGLCBLLN
| Q4 25 | $961.1K | — | ||
| Q3 25 | $-1.2M | $13.8M | ||
| Q2 25 | $-737.9K | — | ||
| Q1 25 | $-824.1K | — | ||
| Q4 24 | $219.2K | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | $-672.3K | — | ||
| Q1 24 | $-37.2K | — |
自由现金流BGLCBLLN
| Q4 25 | $960.1K | — | ||
| Q3 25 | $-1.2M | $6.5M | ||
| Q2 25 | $-759.4K | — | ||
| Q1 25 | $-833.1K | — | ||
| Q4 24 | $215.2K | — | ||
| Q3 24 | $-1.8M | — | ||
| Q2 24 | $-674.1K | — | ||
| Q1 24 | $-59.1K | — |
自由现金流率BGLCBLLN
| Q4 25 | 198.5% | — | ||
| Q3 25 | -48.9% | 7.7% | ||
| Q2 25 | -33.6% | — | ||
| Q1 25 | -39.0% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | -68.5% | — | ||
| Q2 24 | -34.1% | — | ||
| Q1 24 | -2.5% | — |
资本支出强度BGLCBLLN
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.2% | 8.8% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 7.6% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.9% | — |
现金转化率BGLCBLLN
| Q4 25 | — | — | ||
| Q3 25 | — | 2.42× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.38× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGLC
暂无分部数据
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
